Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Kite Pharma: Interpretation of Results from the Interim Look at ZUMA-1 (KITE, Avoid, $60.25)

Overview Kite released a press release with topline data on the interim look at the ZUMA-1 trial. This note interprets information presented in that press release and I would urge you to read it before going on. Key Points: The CR rate at three months for 51 r/r DLBCL patients was 33%. Kite has said […]

«Older Posts
«Older Posts
Search Graphic